# NCT06234605 (NCT06234605)

> A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

No report yet. It can be ordered.

- Drugs tested: HC-7366 plus belzutifan; HC-7366
- Indication: locally advanced or metastatic renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06234605
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: HiberCell, Inc.
- Conditions: Renal Cell Carcinoma
- Interventions: HC-7366; Belzutifan
- Enrollment: 80
- Primary outcome: Determination of MTD and RP2D (combination cohorts only)

## Indexed commentary on NCT06234605 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 posts on X
- 1 YouTube video

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct06234605
